Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
4 hedge funds and large institutions have $1.13M invested in Sio Gene Therapies Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 34 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
87% less capital invested
Capital invested by funds: $8.96M → $1.13M (-$7.83M)
89% less funds holding
Funds holding: 37 → 4 (-33)
97% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JC
JBF Capital
Aspen,
Colorado
|
+$945K |
| 2 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$5.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$3.04M |
| 2 |
NM
Newtyn Management
New York
|
-$1.3M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$870K |
| 4 |
TVWM
Tower View Wealth Management
Shorewood,
Wisconsin
|
-$869K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$757K |
SIOX Hedge Fund Activity: Q1 2023 in Review
4 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q1 2023, worth a combined $1.13M — down 87% from $8.96M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of SIOX and 1 opened new positions — a net loss of 33 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was JBF Capital, adding an estimated $945K. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $3.04M sold.
- 4 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q1 2023, down from 37 in Q4 2022.
- Funds reported $1.13M of Sio Gene Therapies Inc. Common Stock stock for Q1 2023, down 87% quarter-over-quarter.
- 1 fund opened new Sio Gene Therapies Inc. Common Stock positions in Q1 2023 and 34 closed out, a net change of -33 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q1 2023 was JBF Capital, an estimated $945K added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q1 2023 was Rubric Capital Management (New York), an estimated $3.04M sold.
Based on aggregated 13F filings for Q1 2023.